|
ZGNX's Revenue Growth by Quarter and Year
Zogenix Inc 's Revenue results by quarter and year
Select the Comparisons :
|
|
Select the Ratio:
|
|
ZGNX Revenue (in millions $) |
FY 2021 |
FY 2020 |
FY 2019 |
FY 2018 |
IV Quarter |
December |
26.61
|
2.86
|
3.01
|
2.13
|
III Quarter |
September |
22.61
|
1.03
|
4.05
|
1.03
|
II Quarter |
June |
18.79
|
1.09
|
3.16
|
0.83
|
I Quarter |
March |
13.68
|
-6.57
|
3.18
|
0.00
|
FY |
|
81.69
|
-1.59
|
13.40
|
3.99
|
ZGNX Revenue fourth quarter 2021 Y/Y Growth Comment |
Zogenix Inc reported Revenue surge of 830.31% year on year in the fourth quarter 2021, to $ 26.61 millions, this is lower than Zogenix Inc 's recent average Revenue surge of 5.585519069102E+15%.
Looking into fourth quarter 2021 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Zogenix Inc ' s Revenue doubling of 830.31% ranks overall at the positon no. 91 in the fourth quarter 2021.
|
ZGNX Revenue ( Y/Y Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
830.31 % |
-4.98 % |
41.31 % |
- |
III Quarter |
September |
2095.15 % |
-74.57 % |
293.2 % |
-85.55 % |
II Quarter |
June |
1623.85 % |
-65.51 % |
280.72 % |
-69.26 % |
I Quarter |
March |
- |
- |
- |
- |
FY |
|
- |
- |
235.84 % |
-80.84 % |
ZGNX Revenue (Quarter on Quarter Growth %) |
2021
|
2020 |
2019 |
2018 |
IV Quarter |
December |
17.68 % |
177.67 % |
-25.68 % |
106.8 % |
III Quarter |
September |
20.33 % |
-5.5 % |
28.16 % |
24.1 % |
II Quarter |
June |
37.35 % |
- |
-0.63 % |
- |
I Quarter |
March |
378.32 % |
- |
49.3 % |
- |
FY (Year on Year) |
|
- |
- |
235.84 % |
-80.84 % |
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1.0E+17 % |
5.585519069102E+15 % |
-100 % |
|
|
(Dec 31 2017) |
|
Revenue Y/Y Growth Statistics |
High |
Average |
Low |
1.0E+17 % |
5.585519069102E+15 % |
-100 % |
|
|
(Dec 31 2017) |
|
Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021 |
Zogenix Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
4.6893731119994E+16 % |
1.3792273858822E+15 % |
-100 % |
(Mar 31 2018) |
|
|
ZGNX's IV. Quarter Q/Q Revenue Comment |
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.
Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 875. |
|
|
Revenue Q/Q Growth Statistics |
High |
Average |
Low |
4.6893731119994E+16 % |
1.3792273858822E+15 % |
-100 % |
(Mar 31 2018) |
|
|
ZGNX's IV. Quarter Q/Q Revenue Comment |
Zogenix Inc achieved in the IV. Quarter 2021 below company average Revenue jump of 17.68% quarter on quarter, to $ 26.61 millions.
Within Major Pharmaceutical Preparations industry 77 other companies have achieved higher Revenue quarter on quarter growth. While Zogenix Inc 's Revenue growth quarter on quarter, overall rank is 875. |
|
Zogenix Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending (Dec 31 2021) |
12 Months Ending (Sep 30 2021) |
12 Months Ending (Jun 30 2021) |
12 Months Ending (Mar 31 2021) |
12 Months Ending (Sep 30 2020) |
Cumulative Revenue 12 Months Ending |
$ 81.69 |
$ 57.94 |
$ 36.37 |
$ 18.66 |
$ -1.59 |
Y / Y Revenue Growth (TTM) |
- |
- |
2201.58 % |
411.62 % |
- |
Year on Year Revenue Growth Overall
Ranking |
# 109 |
# 0 |
# 25 |
# 30 |
# 161 |
Seqeuential Revenue Change (TTM) |
40.98 % |
59.34 % |
94.84 % |
- |
- |
Seq. Revenue Growth (TTM) Overall
Ranking |
# 391 |
# 52 |
# 33 |
# 67 |
# 0 |
Cumulative Revenue growth
Comment |
Zogenix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 830.31% year on year, to $ 82 millions if the fiscal year would have ended in Dec 31 2021. Zogenix Inc 's trailing twelve months Revenue growth was higher than company's average 108.63% and higher than % growth in Sep 30 2021. But from twelve months ended Sep 30 2021 growth rate was beneth at 40.98 % from $57.94 millions recorded in the period from Sep 30 2021 to Sep 30 2020. There is drop-off in progress, more noticeable as we look at average Q/Q TTM historic rise that is better at108.63%. In the Dec 31 2021 period, Zogenix Inc had cumulative twelve months Revenue of $ 82 millions compare to of $ -2 millions a year ago. There is progress on the way, but very slow one, reporting below standard 40.98 % Revenue advance, from $57.94 millions from the period from Sep 30 2021 to Sep 30 2020 Anvi Rao mentioned.
In the Healthcare sector 37 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 109. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 52 |
Sector |
# 109 |
S&P 500 |
# 391 |
|
Cumulative Revenue growth
Comment |
Zogenix Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 830.31% year on year, to $ 82 millions if the fiscal year would have ended in Dec 31 2021. Zogenix Inc 's trailing twelve months Revenue growth was higher than company's average 108.63% and higher than % growth in Sep 30 2021. But sequential growth rate was slower at 40.98 % from $57.94 millions achieved in twelve months ending a quarter Sep 30 2021 Anvi Rao went on. It appears to be stagnation in progress, more obvious observing the average sequential Revenue rise that is better at108.63%. The progress is even stronger from the previous reporting period showed at 40.98 % rise from $57.94 millions in the period from Sep 30 2021 to Sep 30 2020. In the Dec 31 2021 period, Zogenix Inc had cumulative twelve months Revenue of $ 82 millions compare to of $ -2 millions a year ago. It is progress on the way, but modest, reporting less then usual 40.98 % Revenue increase, from $57.94 millions from the twelve months ending in the quarter before Anvi Rao mentioned.
In the Healthcare sector 37 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 109. |
Revenue TTM Q/Q Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Y/Y Growth Statistics |
High |
Average |
Low |
2201.58 % |
108.63 % |
-111.89 % |
|
|
|
Revenue TTM Q/Q Growth Company Ranking |
Within: |
No. |
Industry |
# 52 |
Sector |
# 109 |
S&P 500 |
# 391 |
Companies with similar Revenue jump for the quarter ending Dec 31 2021 within Healthcare Sector | Y/Y Change % | Revenue for the quarter ending Dec 31 2021 | Kazia Therapeutics Limited | 1,426.13% | $ 1,426.131 millions | Inmune Bio Inc | 1,393.22% | $ 1,393.221 millions | Guardion Health Sciences Inc | 1,213.59% | $ 1,213.587 millions | Moderna Inc | 1,163.44% | $ 1,163.436 millions | Albireo Pharma inc | 1,097.39% | $ 1,097.386 millions | Option Care Health Inc | 1,023.60% | $ 1,023.599 millions | Genfit S a | 1,003.11% | $ 1,003.106 millions | Ethema Health Corporation | 967.17% | $ 967.166 millions | Dynavax Technologies Corporation | 897.80% | $ 897.801 millions | Inspiremd Inc | 789.87% | $ 789.873 millions | Prophase Labs Inc | 774.63% | $ 774.627 millions | Cytokinetics Incorporated | 727.13% | $ 727.135 millions | Theralink Technologies Inc | 706.69% | $ 706.691 millions | Beyondspring Inc | 650.56% | $ 650.556 millions | Meiragtx Holdings Plc | 504.51% | $ 504.513 millions | Guided Therapeutics Inc | 492.00% | $ 492.000 millions | Lftd Partners Inc | 482.17% | $ 482.175 millions | Cardiff Lexington Corporation | 465.13% | $ 465.127 millions | Lumos Pharma Inc | 450.00% | $ 450.000 millions | Baudax Bio Inc | 426.32% | $ 426.316 millions |
|